2. Academic Validation
  3. Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3

Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3

  • Bioorg Med Chem Lett. 2006 Nov 1;16(21):5633-8. doi: 10.1016/j.bmcl.2006.08.022.
Jack J Chen 1,  Kumar D Thakur,  Michael P Clark,  Steven K Laughlin,  Kelly M George,  Roger G Bookland,  Jan R Davis,  Edward J Cabrera,  Vijay Easwaran,  Biswanath De,  Y George Zhang
Affiliations

Affiliation

  • 1 Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd., Mason, OH 45040, USA. jack.01.chen@gmail.com
PMID: 16934457 DOI: 10.1016/j.bmcl.2006.08.022
Abstract

A new class of pyrimidine-based Janus tyrosine kinase 3 (JAK3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK3.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-155951
    99.32%, JAK3抑制剂
    JAK
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z